, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on . The required quorum for the transaction of business at the Annual Meeting is a majority of the voting power of shares of common stock issued and outstanding on the record date.
There was less than the required voting power represented in person or by proxy at the meeting. The Annual Meeting will be reconvened on at and will continue to be held virtually via live audio-only webcast at . The record date for determination of stockholders entitled to vote at the reconvened Annual Meeting remains the close of business on .
At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 48% of the shares of the Company's common stock issued and outstanding as of the record date. Stockholders as of close of business on , the record date for the Annual Meeting, are encouraged to vote as soon as possible via the Internet at or by phone at 1-800-690-6903 (have proxy c.
